Back to table of contents Previous article Next article Communications and UpdatesFull AccessMethylfolate as Adjunctive Treatment in Major DepressionEdward H. Reynolds, M.D., F.R.C.Psych.Edward H. ReynoldsSearch for more papers by this author, M.D., F.R.C.Psych.Published Online:1 May 2013https://doi.org/10.1176/appi.ajp.2013.13010084AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor: As the principal investigator of the only previous placebo-controlled trial of methylfolate as an adjunctive treatment in major depression 22 years ago (1), I appreciated the new trial by Papakostas et al. (2) in the December 2012 issue confirming the efficacy of the vitamin in some resistant depression.Important differences between the two trials raise interesting questions. Our study was for depressed patients with borderline or definite folate deficiency (red blood cell folate levels <200 pg/mL), but Papakostas et al. did not mention the folate status of their patients. I presume that many would not have been folate deficient. We also used 15 mg of methylfolate, but our trial was for 6 months and demonstrated increasing efficacy at 3 and 6 months in contrast to the 60-day study by Papakostas et al.I first reported in 1967 the beneficial effect of the vitamin on mood and some aspects of cognitive and social function in an open trial of folic acid, 5 mg/day for 1 to 3 years, in folate-deficient patients with epilepsy (3). At the Medical Research Council Neuropsychiatry Research Unit, we then showed not only that folate deficiency was common in depression, as had been reported by Carney (4), but that the deficiency was associated with a poor response to antidepressant therapy (5). I subsequently collaborated with Carney and colleagues in demonstrating that depression was the most common reversible neuropsychiatric manifestation of folate-deficient megaloblastic anemia; in confirming that S-adenosylmethionine had antidepressant properties, thus implying that methylation is a key to understanding mood (6); and in identifying a subgroup of patients with depression, high plasma homocysteine levels, folate deficiency, and impaired neurotransmitter metabolism. This culminated in our positive trial of methylfolate, the transport form of folate into the nervous system, as adjunctive therapy in depression (1).A crucial question for the future is to what extent the antidepressant properties of methylfolate depend on the folate status of the patient. Our own pilot observations suggest that methylfolate may have antidepressant properties as monotherapy, irrespective of folate status, but that responders show a greater rise in red cell folate levels than nonresponders (7). An important clue is the mood-elevating properties of nitrous oxide. This euphoriant effect is probably related to the instantaneous inactivation of methionine synthase, leading to an acute rise in methylfolate in the brain (7). Finally, methylation in the nervous system is a key not just to the biology of mood but to other aspects of cognitive function, including dementia. After 45 years, it is time for academic departments of psychiatry to invest more in this nonpharmaceutical approach to mental illness.From the Department of Clinical Neurosciences, King’s College, University of London.The author reports no financial relationships with commercial interests.References1 Godfrey PSA, Toone BK, Carney MWP, Flynn TG, Bottiglieri T, Laundy M, Chanarin I, Reynolds EH: Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990; 336:392–395Crossref, Medline, Google Scholar2 Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, Baer L, Dalton ED, Sacco GR, Schoenfeld D, Pencina M, Meisner A, Bottiglieri T, Nelson E, Mischoulon D, Alpert JE, Barbee JG, Zisook S, Fava M: l-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry 2012; 169:1267–1274Link, Google Scholar3 Reynolds EH: Effects of folic acid on the mental state and fit-frequency of drug-treated epileptic patients. Lancet 1967; 1:1086–1088Crossref, Medline, Google Scholar4 Carney MWP: Serum folate values in 423 psychiatric patients. Br Med J 1967; 4:512–516Crossref, Medline, Google Scholar5 Reynolds EH, Preece JM, Bailey J, Coppen A: Folate deficiency in depressive illness. Br J Psychiatry 1970; 117:287–292Crossref, Medline, Google Scholar6 Reynolds EH, Carney MWP, Toone BK: Methylation and mood. Lancet 1984; 2:196–198Crossref, Medline, Google Scholar7 Reynolds EH: Vitamin B12, folic acid, and the nervous system. Lancet Neurol 2006; 5:949–960Crossref, Medline, Google Scholar FiguresReferencesCited byDetailsCited ByFolic Acid, Folinic Acid, 5 Methyl TetraHydroFolate Supplementation for Mutations That Affect Epigenesis through the Folate and One-Carbon Cycles24 January 2022 | Biomolecules, Vol. 12, No. 2Behavioral and neurochemical effects of folic acid in a mouse model of depression induced by TNF-αBehavioural Brain Research, Vol. 414Depressão e distúrbios do sonoFolic acid ameliorates depression-like behaviour in a rat model of chronic unpredictable mild stress15 January 2020 | BMC Neuroscience, Vol. 21, No. 1Perspectives in Psychiatric Care, Vol. 54, No. 2Problemy reproduktsii, Vol. 24, No. 3Fundamental & Clinical Pharmacology, Vol. 29, No. 6 Volume 170Issue 5 May 2013Pages 560-560 Metrics PDF download History Accepted 1 February 2013 Published online 1 May 2013 Published in print 1 May 2013
Read full abstract